The original success of Viagra undeniably reshaped the pharmaceutical landscape, but investing in companies heavily reliant on generic versions presents a uncertain picture. Although early profits were impressive, the expiration of patents and the rise of cheaper alternatives have weakened market share. Consequently, a thorough assessment of ongoin